source
- Estuary debuts with $103M to develop kidney disease gene therapiesEstuary Biotherapeutics raised the curtain on Friday with $103 million to support the advancement of two preclinical gene therapy candidates for the most common type of inherited kidney disease. Th…Endpoints · 4d ago↗ source
- CSL agrees $355M upfront deal to co-develop Alentis anti-fibrosis drug for kidney and liverCSL, an Australian drugmaker, announced a partnership with Alentis Therapeutics that includes a $355 million upfront payment. Under the agreement, CSL will co-develop Alentis's anti-fibrosis candi…